Clinical Trial Update: 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating head-to-head diagnostic efficacy of 68Ga-PSMA-11 PET imaging versus mpMRI for diagnosing prostate cancer. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Prostate Cancer (Adenocarcinoma) | Phase 2, Phase 3 | Status: RECRUITING